MedPath

Cardiac Involvement in Wilson's Disease

Not Applicable
Recruiting
Conditions
Wilson's Disease
Registration Number
NCT05493605
Lead Sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Brief Summary

Heart damage by copper accumulation has been reported in Wilson's Disease. However, the disease epidemiology is still poorly understood. A number of studies on pediatric populations have not shown any significant cardiac involvement apart from early dysautonomia. This could suggest that the clinical manifestations related to the copper accumulation in the heart appears with the duration of the disease. Case-control studies on adult populations have highlighted various electrocardiographic (ECG) abnormalities more frequent in patients with Wilson's Disease than in healthy volunteers, but all these studies involved small number of patients (maximum 60). The hypothesis is that there is cardiac involvement in Wilson's Disease, requiring screening, follow-up and appropriate support.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
150
Inclusion Criteria
  • Adult patient with Wilson's disease confirmed by a Leipzig score ≥ 4
  • Express consent to participate in the study by the patient or legal guardian in the case of patients under guardianship or by the patient assisted by his curator in the case of patients under guardianship
  • Member of or beneficiary of a Social Security scheme
Exclusion Criteria
  • Absolute or relative contraindication to MRI or contrast media
  • Pregnant, parturient or breast-feeding women: a urine pregnancy test will be carried out in women of childbearing age
  • Patient with hepatic decompensation (Child-Pugh score stage C)
  • Patient in neuro-psychiatric decompensation

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Electrocardiogram - Day 0Day 0

Description of abnormalities (frequency and percentage)

Contrast-enhanced cardiac MRI - Year 3Year 3

Description of abnormalities (frequency and percentage)

Electrocardiogram - Year 3Year 3

Description of abnormalities (frequency and percentage)

Transthoracic echocardiography - Day 0Day 0

Description of abnormalities (frequency and percentage)

Implantable loop recorder or ECG holter recorder- Day 21Day 21

Description of abnormalities (frequency and percentage) The device will record from Day 0 to Day 21 Implantable loop recorder assessment will be only performed on patients with syncope.

Chest computed tomography scan without contrast - Day 0Day 0

Percentage of patients with abnormal coronary artery calcium score

Calcium score : The higher the coronary calcium score, the greater the cardiovascular risk. A score of 0 (min) means that no calcium is seen in the heart. A score greater than 300 is a sign of very high to severe disease.

Lying and standing blood pressure tests - Year 3Year 3

Description of abnormalities (frequency and percentage)

Contrast-enhanced cardiac MRI - Day 0Day 0

Description of abnormalities (frequency and percentage)

Clinical examination - Day 0Day 0

Description of abnormalities (frequency and percentage)

Blood and urine tests - Day 0Day 0

Description of abnormalities (frequency and percentage) Blood tests performed : lipid profile, glycosylated hemoglobin (HbA1C), cardiac enzymes (troponin C, NT-proBNP), ultra-sensitive C-reactive protein, sodium level, potassium level, urea and creatinine clearance, TSH, fibrinogen Urine test performed : proteinuria

Lying and standing blood pressure tests - Day 0Day 0

Description of abnormalities (frequency and percentage)

Transthoracic echocardiography - Year 3Year 3

Description of abnormalities (frequency and percentage)

Chest computed tomography scan without contrast - Year 3Year 3

Percentage of patients with abnormal coronary artery calcium score

Calcium score : The higher the coronary calcium score, the greater the cardiovascular risk. A score of 0 (min) means that no calcium is seen in the heart. A score greater than 300 is a sign of very high to severe disease.

Clinical examination - Year 3Year 3

Description of abnormalities (frequency and percentage)

Blood and urine tests - Year 3Year 3

Description of abnormalities (frequency and percentage) Blood tests performed : lipid profile, glycosylated hemoglobin (HbA1C), cardiac enzymes (troponin C, NT-proBNP), ultra-sensitive C-reactive protein, sodium level, potassium level, urea and creatinine clearance, TSH, fibrinogen Urine test performed : proteinuria

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Fondation Adolphe de Rothschild

🇫🇷

Paris, France

Fondation Adolphe de Rothschild
🇫🇷Paris, France
Aurélia Poujois
Contact
0148036656
apoujois@for.paris

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.